AstraZeneca Up 6% After Hours on Tagrisso Data From Lung Cancer Phase III Trial
May 28 2020 - 6:13PM
Dow Jones News
By Josh Beckerman
AstraZeneca PLC shares were up 6% after hours to $56.53 as the
company said its Tagrisso drug "demonstrated unprecedented patient
benefit in the adjuvant treatment of EGFR-mutated lung cancer" in
the Phase III ADAURA trial.
The company said Tagrisso "demonstrated a statistically
significant and clinically meaningful improvement in disease-free
survival."
AstraZeneca said the results "demonstrate for the first time in
a global trial that an EGFR inhibitor can change the course of
early-stage EGFR-mutated lung cancer and provide hope for a cure,"
and the company is "discussing these outstanding data with
regulatory authorities."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
May 28, 2020 17:58 ET (21:58 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
